C-Rad AB (publ)
Research C-Rad AB (publ) (CRAD-B) on Bullrun: valuation model: 4.6% overvalued, market cap SEK 1.18B, P/E 23.5, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRAD-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal4.6% overvalued
- Market capSEK 1.18B
- P/E23.5
- Dividend yield0.3%
- Financial periodQ2 2026
- RevenueSEK 121.70M
- Net incomeSEK 24.20M
- Free cash flowSEK 10.10M
- Gross margin74.9%
Valuation Snapshot
Bullrun's latest valuation model marks C-Rad AB (publ) as 4.6% overvalued; latest market cap is SEK 1.18B; P/E is 23.5; dividend yield is 0.3%.
Peer valuation comparison
Latest P/E is 23.45x versus a Healthcare sector median of 24.46x (4.1% below).
Latest dividend yield is 0.28% versus a Healthcare sector median of 2.11% (86.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 442.00M | SEK 10.40M | n/a | 69.9% | n/a | SEK 171.22M | SEK 9.42M | SEK 347.24M |
| FY2024 | SEK 469.00M | SEK 56.45M | SEK 29.21M | 67.6% | 1.67 | SEK 150.89M | SEK 9.00M | SEK 324.99M |
| FY2023 | SEK 424.62M | SEK 35.53M | SEK 29.28M | 64.6% | 1.05 | SEK 129.36M | n/a | SEK 271.18M |
| FY2022 | SEK 301.33M | SEK 7.48M | SEK 8.58M | 64.8% | 0.22 | SEK 121.90M | n/a | SEK 242.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 1.18B | 23.5 | 0.3% | 0.1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.1 SEK, yield 0.3%.
About C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is C-Rad AB (publ) overvalued or undervalued?
Bullrun's valuation model currently marks C-Rad AB (publ) as 4.6% overvalued.
What is C-Rad AB (publ)'s market cap?
C-Rad AB (publ)'s market capitalization is SEK 1.18B.
What is C-Rad AB (publ)'s P/E ratio?
C-Rad AB (publ)'s price-to-earnings (P/E) ratio is 23.5.
Does C-Rad AB (publ) pay a dividend?
C-Rad AB (publ) has a dividend yield of 0.3%.
What does C-Rad AB (publ) do?
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.